Clinical Trials · NCT02963935
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 282
- Start date
- Feb 2017
- Locations
- 10 sites, United States
- Primary endpoint
- Change in Body Weight (%)